MRI to Measure Treatment With Antibiotics in Alzheimer's Disease (DARAD-MRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00692588|
Recruitment Status : Completed
First Posted : June 6, 2008
Last Update Posted : April 6, 2011
To study the changes in brain structure and function using MRI scans in patients treated for Alzheimer's disease.
A pilot study of treating Alzheimer's disease with antibiotics showed some promise that this treatment could delay the deterioration of the mind with this disease. This study is being replicated on a larger scale, providing a more definitive answer to this question. In addition to looking at changes of the mind (through cognitive tests), we would like to use MRI scans in these patients before and after treatment to study the structural changes and the chemical changes in the brain. This would provide a non-invasive look at the bran processes that protect the brain from the effect of Alzheimer's as well as confirming that the disease has been modified with treatment.
The novel treatment of Alzheimer's with antibiotics has provided a potential breakthrough in the field. In addition to verifying changes in the brain, MRI scans can observe HOW this process could occur, thus opening doors to other new treatments for Alzheimer's and perhaps even cures.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||58 participants|
|Observational Model:||Case Control|
|Official Title:||Magnetic Resonance Imaging to Measure Treatment Effects of Doxycycline and Rifampicin in Alzheimer's Disease|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
U.S. FDA Resources
Subjects who received placebo in DARAD Trial
Subjects who received doxycycline in DARAD Trial
Subjects who received rifampicin in DARAD Trial
Doxycycline and Rifampicin
Subjects who received doxycycline and rifampicin in DARAD Trial
- Changes in MRI Pre Vs Post Treatment [ Time Frame: 1 Year ]
- Comparison of Normal Controls Vs Alzheimer's Disease using MRI [ Time Frame: 1 Year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00692588
|St. Joseph's Healthcare|
|Hamilton, Ontario, Canada, L8N 4A6|
|Principal Investigator:||Mohammed A Warsi, (Hon)BSc, MSc, MD, FRCP(C)||McMaster University|
|Study Director:||Michael D Noseworthy, (Hon)BSc, MSc, PhD||St. Joseph's Hospital|
|Study Director:||William Molloy, MBBch, MRCP, FRCP(C)||St. Peters Hospital|